Can we prevent immunogenicity of human protein drugs?

Annals of the Rheumatic Diseases

Volumn 69, Issue SUPPL. 1, 2010, Pages

  Scott, D W ^a   De Groot, A S ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HUMAN MONOCLONAL ANTIBODY; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; B7 ANTIGEN; CD86 ANTIGEN; HLA ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

B LYMPHOCYTE; GENE THERAPY; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATIC DISEASE; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; BINDING AFFINITY; CELLULAR IMMUNITY; DRUG RESPONSE; HLA SYSTEM; IMMUNOREACTIVITY; IMMUNOSTIMULATION; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN TARGETING;

ANTIBODIES, MONOCLONAL; DRUG DESIGN; EPITOPES, T-LYMPHOCYTE; GENE THERAPY; HUMANS; IMMUNE TOLERANCE;

EID: 75749087940     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2009.117564     Document Type: Review

References (34)

1. Gallucci S, Matzinger P. Danger signals: SOS to the immune system. Curr Opin Immunol 2001;13:114-9.
2. Zhong G, Reis e Sousa C, Germain RN. Antigen-unspecific B cells and lymphoid dendritic cells both show extensive surface expression of processed antigen-major histocompatibility complex class II complexes after soluble protein exposure in vivo or in vitro. J Exp Med 1997;186:673-82.
3. Ruprecht CR, Lanzavecchia A. Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur J Immunol 2006;36:810-6.
4. Magdelaine-Beuzelin C, Vermeire S, Goodall M, et al. IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab. Pharmacogenet Genomics 2009;19:383-7.
5. Villalobos AP, Gunturi SR, Heavner GA. Interaction of polysorbate 80 with erythropoietin: a case study in protein-surfactant interactions. Pharm Res 2005;22:1186-94.
6. Brooks SA. Strategies for analysis of the glycosylation of proteins: current status and future perspectives. Mol Biotechnol 2009 Jun 9. [Epub ahead of print].
7. Mueller R, Karle A, Vogt A, et al. Evaluation of the immuno-stimulatory potential of stopper extractables and leachables by using dendritic cells as readout. J Pharm Sci 2009 Feb 18. [Epub ahead of print].
8. Gilliland LK, Walsh LA, Frewin MR, et al. Elimination of the immunogenicity of therapeutic antibodies. J Immunol 1999;162:3663-71.
9. Ulmer JB. Enhancement of vaccine potency through improved delivery. Enhancement of vaccine potency through improved delivery. Expert Opin Biol Ther 2004;4:1045-51.
10. Hay CR. The epidemiology of factor VIII inhibitors. Haemophilia 2006;12(Suppl 6):23-8.
11. Münz C, Lünemann JD, Getts MT, et al. Antiviral immune responses: triggers of or triggered by autoimmunity? Nat Rev Immunol 2009;9:246-58.
12. Rapin N, Hoof I, Lund O, et al. MHC motif viewer. Immunogenetics 2008;60:759-65.
13. De Groot AS, Martin W. Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics. Clin Immunol 2009;131:189-201.
14. Koren E, De Groot AS, Jawa V, et al. Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein. Clin Immunol 2007;124:26-32.
15. De Groot AS, McMurry J, Moise L. Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates. Curr Opin Pharmacol 2008;8:620-6.
16. De Groot AS, Moise L. Prediction of immunogenicity for therapeutic proteins: state of the art. Curr Opin Drug Discov Devel 2007;10:332-40.
17. De Groot AS, Knopf PM, Martin W. De-immunization of therapeutic proteins by T-cell epitope modification. Dev Biol (Basel) 2005;122:171-94.
18. Jones TD, Crompton LJ, Carr FJ, et al. Deimmunization of monoclonal antibodies. Methods Mol Biol 2009;525:405-23.
19. Tangri S, LiCalsi C, Sidney J, et al. Rationally engineered proteins or antibodies with absent or reduced immunogenicity. Curr Med Chem 2002;9:2191-9.
20. Collen D, Bernaerts R, Declerck P, et al. Recombinant staphylokinase variants with altered immunoreactivity. I: Construction and characterization. Circulation 1996;94:197-206.
21. Podojil JR, Turley DM, Miller SD. Therapeutic blockade of T-cell antigen receptor signal transduction and costimulation in autoimmune disease. Adv Exp Med Biol 2008;640:234-51.
22. Brusko TM, Putnam AL, Bluestone JA. Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol Rev 2008;223:371-90.
23. Tsuji NM, Kosaka A. Oral tolerance: intestinal homeostasis and antigen-specific regulatory T cells. Trends Immunol 2008;29:532-4.
24. Chatenoud L, Bluestone JA. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol 2007;7:622-32.
25. Alegre ML, Fallarino F. Mechanisms of CTLA-4-Ig in tolerance induction. Curr Pharm Des 2006;12:149-60.
26. Pechhold K, Koczwara K. Immunomodulation of autoimmune diabetes by dendritic cells. Curr Diab Rep 2008;8:107-13.
27. Skupsky J, Su Y, Lei TC, et al. Tolerance induction by gene transfer to lymphocytes. Curr Gene Ther 2007;7:369-80.
28. Borel Y. Haptens bound to self IgG induce immunologic tolerance, while when coupled to syngeneic spleen cells they induce immune suppression. Immunol Rev 1980;50:71-104.
29. Zambidis ET, Scott DW. Epitope-specific tolerance induction with an engineered immunoglobulin. Proc Natl Acad Sci USA 1996;93:5019- 24.
30. Zambidis ET, Kurup A, Scott DW. Genetically transferred central and peripheral immune tolerance via retroviral-mediated expression of immunogenic epitopes in hematopoietic progenitors or peripheral B lymphocytes. Mol Med 1997;3:212-24.
31. Soukhareva N, Jiang Y, Scott DW. Treatment of diabetes in NOD mice by gene transfer of Ig-fusion proteins into B cells: role of T regulatory cells. Cell Immunol 2006;240:41-6.
32. De Groot AS, Moise L, McMurry JA, et al. Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes". Blood 2008;112:3303-11.
33. Ephrem A, Chamat S, Miquel C, et al. Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood 2008;111:715-22.
34. Kaveri SV, Lacroix-Desmazes S, Bayry J. The antiinflammatory IgG. N Engl J Med 2008;359:307-9.